Search results
Showing 7666 to 7680 of 7708 results
Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab, a drug that reduces the chance of it returning.
More than 400 people could benefit from life-extending advanced lung cancer treatment
Durvalumab recommended as an option for treating non-small-cell lung cancer.
Hundreds of thousands set to benefit from new treatment to prevent heart attacks and strokes
NICE has published final draft guidance which recommends icosapent ethyl for reducing the risk of heart attacks and strokes in adults who have raised blood fats.
Hundreds of people with some forms of urothelial cancer to receive new treatment
People with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment – avelumab – following its recommendation for funding
Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment under new NICE guidance.
Around 105,000 people with type 1 diabetes could benefit from NICE’s draft recommendation
KardiaMobile recommended for people having antipsychotic medication
NICE publishes first draft guidance from its Early Value Assessment pilot project recommending smartphone-linked ECG device
Colorectal cancer patients with rare mutations to benefit from life-extending treatment
NICE recommends pembrolizumab for colorectal cancer patients with rare mutations.
Children and young people set to benefit from new treatment for peanut allergy
Children and young people aged between 4 and 17 with a peanut allergy could benefit from Palforzia, a new treatment which can help build up their tolerance to peanut.
NICE and the GetReal Institute: facilitating the adoption and implementation of real-world evidence in health care decision-making.
NICE to become single point of access for Covid-19 guidance and advice
NICE announced that it is to host a new, single point of advice on caring for people with Covid-19 and the management of Covid-19 in a variety of clinical settings.
NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.
NICE's flexibility in evaluation of new health tech and fairer patient access
Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
NICE recommends treatment options for severe pregnancy sickness
Nausea and vomiting, often referred to as morning sickness, is common in pregnancy. Close to 80% of pregnant women experience these symptom.